<DOC>
	<DOCNO>NCT00030511</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy surgery may shrink tumor remove surgery . PURPOSE : Phase II trial study effectiveness combine radiation therapy fluorouracil surgery treat patient primary recurrent bile duct cancer .</brief_summary>
	<brief_title>Radiation Therapy Fluorouracil Before Surgery Treating Patients With Primary Recurrent Bile Duct Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine pathologic response rate patient primary recurrent biliary duct carcinoma treat neoadjuvant radiotherapy fluorouracil follow surgical resection . - Determine tumor response , morbidity , failure pattern ( locoregional v distant ) , survival patient treat regimen . - Determine toxic effect regimen patient . OUTLINE : This multicenter study . Patients undergo radiotherapy daily five day week 5.5 week . Patients receive fluorouracil IV 12 hour day radiotherapy administer . Four six week completion chemoradiotherapy , patient undergo surgical resection . Patients residual disease resection may undergo boost radiotherapy . Patients follow every 12 week disease progression every 16 week disease progression . PROJECTED ACCRUAL : A total 20-47 patient accrue study within 2.5 year .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary recurrent biliary duct carcinoma proximal , middle , distal bile duct Measurable evaluable disease consider resectable No distant metastases No noncontiguous liver metastasis Resectable extension adjacent liver allow No metastasis peritoneal cavity No Bismuth type 4 lesion metastasis celiac axis paraaortic lymph nod No tumor encasement portal vein hepatic artery No gross ascites PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : No cirrhosis No active cholangitis No fever sign infection biliary drainage system Measurement Creactive protein optimal Bilirubin le 3 mg/dL Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 60 mL/min Other : Not pregnant nursing Fertile patient must use effective barrier contraception 3 month study No weight loss great 20 % ideal body weight No active duodenal gastric ulcer No prior concurrent primary malignancy except adequately treat carcinoma situ cervix basal cell carcinoma PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>localize resectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>localize extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
</DOC>